About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/16/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/16/2021.

Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer

Clinicaltrials.gov identifier NCT03927885

Recruitment Status Recruiting

First Posted April 25, 2019

Last update posted September 27, 2019

Study Description

Brief summary:

This phase II/III trial studies an open labeled placebo to see how well it works compared with waitlist control in reducing cancer related fatigue in patients with cancer that has spread to other places in the body. A placebo is not a drug and is not designed to treat any disease or illness. Recent studies have found that cancer related fatigue symptoms in cancer survivors are improved with open labeled placebo (that is, patients know they are taking a placebo). It is not yet known how well an open labeled placebo works when compared with waitlist control in reducing cancer related fatigue.

  • Condition or Disease:Advanced Malignant Solid Neoplasm
    Cancer Fatigue
    Metastatic Malignant Solid Neoplasm
    Recurrent Malignant Solid Neoplasm
    Pain
  • Intervention/Treatment: Other: Placebo
    Other: Quality-of-Life Assessment
    Other: Questionnaire Administration
    Other: Waiting List
  • Phase: Phase 2/Phase 3
Detailed Description

PRIMARY OBJECTIVE: I. To determine the effects of open labeled placebo one tablet twice a day (OLP) compared to waitlist control (WLC) for reducing cancer-related fatigue (CRF) as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) subscale in fatigued advanced cancer patients at the end of one week. SECONDARY OBJECTIVES: I. To determine the preliminary efficacy open labeled placebo (OLP) and WLC on various fatigue dimensions - (Multidimensional Fatigue Symptom Inventory, MFSI-SF), depression (The Center for Epidemiologic Studies - Depression [CES-D]), cancer symptoms (Edmonton Symptom Assessment System [ESAS]), function and strength (six minute walk test, and 30-sec chair stand test), Global Symptom Evaluation (GSE), and quality of life (Functional Assessment of Cancer Therapy - General [FACT-G]) in these advanced cancer patients. II. To determine effects of OLP on fatigue symptom composite score (ESAS fatigue, pain and depression) at the end of 1st and 4th week. III. To examine the adherence and safety for the OLP as treatment for cancer related fatigue. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive open labeled placebo orally (PO) twice daily (BID) for 4 weeks in the absence of disease progression. ARM II: Patients are assigned to a waiting list during week 1. Beginning in week 2, patients receive open labeled placebo PO BID for 3 weeks in the absence of disease progression.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 100 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Supportive Care
  • Official Title: Open Labeled Placebo for Treatment of Cancer Related Fatigue in Patients With Advanced Cancer
  • Actual Study Start Date: March 2019
  • Estimated Primary Completion Date: August 2021
  • Estimated Study Completion Date: August 2021
Arms and interventions
Arm Intervention/treatment
Experimental: Arm I (open labeled placebo)
Patients receive open labeled placebo PO BID for 4 weeks in the absence of disease progression.
Other: Placebo
Given open labeled placebo PO

Other: Quality-of-Life Assessment
Ancillary studies

Other: Questionnaire Administration
Ancillary studies
Active Comparator: Arm II (waiting list, open labeled placebo)
Patients are assigned to a waiting list during week 1. Beginning in week 2, patients receive open labeled placebo PO BID for 3 weeks in the absence of disease progression.
Other: Placebo
Given open labeled placebo PO

Other: Quality-of-Life Assessment
Ancillary studies

Other: Questionnaire Administration
Ancillary studies

Other: Waiting List
Assigned to a waiting list
Outcome Measures
  • Primary Outcome Measures: 1. Change in cancer related fatigue [ Time Frame: Baseline up to 1 week ]
    Will use t-tests to assess the mean changes and standard deviations from baseline to follow-up between the groups.
  • Secondary Outcome Measures: 1. Change in quality of life (QOL) [ Time Frame: Baseline up to 4 weeks ]
    Will use t-tests to assess the mean changes and standard deviations from baseline to follow-up between the groups. The percentage of patients who report 'better' in each group will be reported. Will also compare the % of patients who report 'somewhat better' to "a great deal better" in each group and report the difference between groups (chi-square tests).
  • 2. Change in function strength [ Time Frame: Baseline up to 4 weeks ]
    Will use t-tests to assess the mean changes and standard deviations from baseline to follow-up between the groups. The percentage of patients who report 'better' in each group will be reported. Will also compare the % of patients who report 'somewhat better' to "a great deal better" in each group and report the difference between groups (chi-square tests).
  • 3. Change in Global Symptom Evaluation (GSE) [ Time Frame: Baseline up to 4 weeks ]
    Will use t-tests to assess the mean changes and standard deviations from baseline to follow-up between the groups. The percentage of patients who report 'better' in each group will be reported. Will also compare the % of patients who report 'somewhat better' to "a great deal better" in each group and report the difference between groups (chi-square tests).
  • 4. Changes in cluster composite scores of sleep disturbance [ Time Frame: Baseline up to 1 week ]
    The primary comparison will be using changes in cluster composite scores of sleep disturbance from baseline to end of week 1 between the placebo arm and waitlist control arm. Exploratory graphical analysis of the data will be done. If the assumptions of the t-test are violated, will use the Wilcoxon rank sum test.
  • 5. Changes in cluster composite scores of fatigue [ Time Frame: Baseline up to 1 week ]
    The primary comparison will be using changes in cluster composite scores of fatigue from baseline to end of week 1 between the placebo arm and waitlist control arm. Exploratory graphical analysis of the data will be done. If the assumptions of the t-test are violated, will use the Wilcoxon rank sum test.
  • 6. Changes in cluster composite scores of pain [ Time Frame: Baseline up to 1 week ]
    The primary comparison will be using changes in cluster composite scores of pain from baseline to end of week 1 between the placebo arm and waitlist control arm. Exploratory graphical analysis of the data will be done. If the assumptions of the t-test are violated, will use the Wilcoxon rank sum test.
  • 7. Changes in cluster composite scores of depression [ Time Frame: Baseline up to 1 week ]
    The primary comparison will be using changes in cluster composite scores of depression from baseline to end of week 1 between the placebo arm and waitlist control arm. Exploratory graphical analysis of the data will be done. If the assumptions of the t-test are violated, will use the Wilcoxon rank sum test.
  • 8. Adherence [ Time Frame: Up to 4 weeks ]
    Will use a chi-square to test the difference in adherence between each placebo group versus waitlist control group.
  • 9. Incidence of adverse events [ Time Frame: Up to 4 weeks ]
    Will calculate the chi-square statistic to test the difference in adverse events between placebo group versus waitlist control group.
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- Patient with a diagnosis of advanced cancer (metastatic or recurrent incurable solid
tumors)

- Presence of fatigue of >= 4/10 on Edmonton Symptom Assessment System (ESAS) Fatigue
item (0-10 severity scale)

- Patient should describe fatigue as being present for a minimum of 2 weeks prior to
screening

- Uncontrolled pain; patient is on opioids for the treatment of cancer pain, he/she must
have had no major dose change (> 25%) for at least 48 hours prior to study entry.
Change in opioid dose after study entry is allowed

- Patient must be willing to engage in telephone follow up with research staff

- Patient must have telephone access to be contacted by the research staff

- Hemoglobin level of >= 9 g/dL. Patient may receive packed red blood cell (PRBC)
transfusion so as to have hemoglobin level of >= 9 g/dL so at participate in the study

Exclusion Criteria:

- Surgery, or pain relieving procedures within 2 weeks of entry into the study or during
the study period

- Patients with history of substance abuse (Cut down, Annoyed, Guilty, Eye opener [CAGE]
>= 2+), cognitively impaired (MD Anderson Symptom [MDAS] > 7)

Contacts and Locations
Contacts

Contact: Sriram Yennu 713-792-6085 syennu@mdanderson.org

Locations

United States, Texas
M D Anderson Cancer Center
Houston

Sponsors and Collaborators

M.D. Anderson Cancer Center

National Cancer Institute (NCI)

Investigators

Principal Investigator: Sriram Yennu M.D. Anderson Cancer Center

More Information
  • Responsible Party: M.D. Anderson Cancer Center
  • ClinicalTrials.gov Identifier: NCT03927885 History of Changes
  • Other Study ID Numbers: 2018-0526, NCI-2019-01027, 2018-0526, P30CA016672
  • First Posted: April 25, 2019 Key Record Dates
  • Last Update Posted: September 27, 2019
  • Last Verified: September 2019
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Fatigue Neoplasms